Response Genetics, Inc. Announces the Appointment of David Gandara, M.D. to Its Board of Directors

LOS ANGELES--(BUSINESS WIRE)--Response Genetics, Inc. (NASDAQ: RGDX), a company focused on the development of molecular diagnostic tests for cancer, announced today the appointment of David Gandara, M.D. to its Board of Directors. Dr. Gandara, a well-known expert in lung cancer and developmental therapeutics, brings significant medical and clinical development expertise in oncology to Response Genetics. He is currently a Professor of Medicine at the University of California, Davis School of Medicine. He is also the Director of Clinical Research, and the Director of the Thoracic Oncology Program at the U.C. Davis Cancer Center.
MORE ON THIS TOPIC